Literature DB >> 3148711

Multiple cytokine activities and loss of interleukin 2 inhibitor in synovial fluids of patients with rheumatoid arthritis.

N Yamagata1, K Kobayashi, T Kasama, T Fukushima, M Tabata, I Yoneya, Y Shikama, S Kaga, M Hashimoto, K Yoshida.   

Abstract

Attempts to detect immune mediators in rheumatoid arthritis synovial fluids (RA-SF) by bioassays have yielded conflicting results, and so we analyzed the immune reactions occurring within rheumatoid joints using monospecific immunoassays for cytokines such as interleukin 1 beta (IL-1 beta), interleukin 2 (IL-2) and gamma interferon (gamma-IFN). Furthermore, we examined the IL-2 inhibitors to clarify the immunoregulatory mechanism in the lesion. SF from active RA contained a significant amount of IL-1 beta and IL-2 but not gamma-IFN. In contrast IL-2 inhibitor activity was depressed in RA-SF regardless of clinical disease activity. Our results suggest that cytokine overproduction and deficiency of inhibitory signals may result in the overactivity of cytokines and the overactivity may participate in the joint lesions of RA.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3148711

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  13 in total

1.  Neutrophils from the synovial fluid of patients with rheumatoid arthritis express the high affinity immunoglobulin G receptor, Fc gamma RI (CD64): role of immune complexes and cytokines in induction of receptor expression.

Authors:  J A Quayle; F Watson; R C Bucknall; S W Edwards
Journal:  Immunology       Date:  1997-06       Impact factor: 7.397

Review 2.  Rheumatology.

Authors:  R A Asherson; R Cervera; D P D'Cruz; G R Hughes
Journal:  Postgrad Med J       Date:  1991-02       Impact factor: 2.401

3.  Activation of the neutrophil myeloperoxidase-H2O2 system by synovial fluid isolated from patients with rheumatoid arthritis.

Authors:  H L Nurcombe; R C Bucknall; S W Edwards
Journal:  Ann Rheum Dis       Date:  1991-04       Impact factor: 19.103

4.  The effect of gold treatment on monocyte interleukin-1 production in rheumatoid arthritis. A prospective study.

Authors:  V A Danis; A J Kulesz; D E Kelly; D S Nelson; P M Brooks
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

5.  Chemokine expression in rheumatoid arthritis (RA): evidence of RANTES and macrophage inflammatory protein (MIP)-1 beta production by synovial T cells.

Authors:  E Robinson; E C Keystone; T J Schall; N Gillett; E N Fish
Journal:  Clin Exp Immunol       Date:  1995-09       Impact factor: 4.330

6.  Neutrophils isolated from the synovial fluid of patients with rheumatoid arthritis: priming and activation in vivo.

Authors:  H L Nurcombe; R C Bucknall; S W Edwards
Journal:  Ann Rheum Dis       Date:  1991-03       Impact factor: 19.103

7.  Nucleoprotein Diet Ameliorates Arthritis Symptoms in Mice Transgenic for Human T-Cell Leukemia Virus Type I (HTLV-1).

Authors:  Hirokazu Ohtaki; Sachiko Yofu; Tomoya Nakamachi; Kazue Satoh; Ai Shimizu; Hiroyoshi Mori; Atsushi Sato; Yoichiro Iwakura; Masaji Matsunaga; Seiji Shioda
Journal:  J Clin Biochem Nutr       Date:  2010-02-24       Impact factor: 3.114

8.  Kinetics of cytokine secretion by mononuclear cells of the blood from rheumatoid arthritis patients are different from those of healthy controls.

Authors:  S Ruschen; W Stellberg; H Warnatz
Journal:  Clin Exp Immunol       Date:  1992-07       Impact factor: 4.330

9.  Activation of neutrophil reactive-oxidant production by synovial fluid from patients with inflammatory joint disease. Soluble and insoluble immunoglobulin aggregates activate different pathways in primed and unprimed cells.

Authors:  J Robinson; F Watson; R C Bucknall; S W Edwards
Journal:  Biochem J       Date:  1992-09-01       Impact factor: 3.857

10.  Interleukin-8 (IL-8) in synovial fluid of rheumatoid and nonrheumatoid joint effusions.

Authors:  C A Verburgh; M H Hart; L A Aarden; A J Swaak
Journal:  Clin Rheumatol       Date:  1993-12       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.